{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["38(4)"],"submitter":["Jameson A"],"funding":["Bradford District Care NHS Foundation Trust &amp; University of Bradford Scholarship"],"pubmed_abstract":["<h4>Background</h4>Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx antipsychotics').<h4>Aims</h4>This study aims to investigate differences between demographic groups prescribed 'CYP2D6-PGx antipsychotics' and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance.<h4>Methods</h4>A cross-sectional study took place extracting data from 243 patients' medical records to explore psychosis drug prescribing, inc"],"journal":["Journal of psychopharmacology (Oxford, England)"],"pagination":["382-394"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11010551"],"repository":["biostudies-literature"],"pubmed_title":["Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study."],"pmcid":["PMC11010551"],"pubmed_authors":["Faisal M","Cardno AG","Sagoo GS","Fylan B","Jameson A","Sohal J","Dalton C","McLean SL","Bristow GC"],"additional_accession":[]},"is_claimable":false,"name":"Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.","description":"<h4>Background</h4>Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx antipsychotics').<h4>Aims</h4>This study aims to investigate differences between demographic groups prescribed 'CYP2D6-PGx antipsychotics' and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance.<h4>Methods</h4>A cross-sectional study took place extracting data from 243 patients' medical records to explore psychosis drug prescribing, inc","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2025-04-19T20:25:39.227Z","creation":"2025-04-19T20:25:39.227Z"},"accession":"S-EPMC11010551","cross_references":{"pubmed":["38494658"],"doi":["10.1177/02698811241238283"]}}